Doperidol    (Tablets, Oral Drops)

Each tablet contains 5, 10 or 20mg haloperidol.
Each 1ml drops contains 2mg haloperidol.

Doperidol is a neuroleptic butyrophenon derivative, with a wide-range of action. It is indicated in the following cases:

  • Schizophrenia.
  • Mental or behavioral disorders: aggression, hyperactivity in the mentally-retarded and patients with organic brain damage.
  • Restless and agitation in the elderly.

Dosage for all indications should be individually determined according to the age, severity of symptoms, previous response to other neuroleptics. Normal starting dose should be half of the normal dose, followed by gradual titration to achieve optimal response.
(Each 30 drops of Doperidol Drops contains 2 mg haloperidol)

  • Initial dose: 0.5 - 5mg daily divided into 2 - 3 doses.
  • Moderate symptomatology: 1.5 - 3mg daily divided into 2 - 3 doses.   
  • Severe symptomatology (resistant patients): 3 - 5mg daily divided into 2 - 3 doses. In adolescents, who in certain cases, may require up to 30mg or exceptionally up to 60mg daily. In resistant schizophrenia daily dosage up to 100mg (rarely 200mg) may be necessary to achieve an optimal response.
  • Maintenance dose: Once satisfactory control of symptoms has been achieved, dosage should be gradually reduced to the lowest effective maintenance dose, often as low as 5 - 10mg daily. Too rapid dosage reduction should be avoided.


  • Initial dose: 1.5 - 3mg divided into 2 - 3 doses.
  • Maintenance dose: 1.5 - 50mg daily.


  • Maintenance dose: 0.025 - 0.050 mg/kg daily, divided into two doses, half in the morning and the other half in the evening. Dosage should not be more than 10mg daily.

Side Effects:
Doperidol may cause dystonic reaction, dizziness, headache, rarely oedema, skin rash, jaundice, and impairment of sexual function, haematological disorders, extrapyramidal dysfunction.

Drug Interactions:
Doperidol increases the central nervous system depression produced by other C.N.S. depressant drugs including alcohol, hypnotics, sedatives or opioid analgesics. An enhanced C.N.S. effect, when combined with methyl dopa has been reported. Neurotoxic reactions and hyperthermia during combined treatment with lithium have been reported. Doperidol do not dissolve quickly with tea and coffee, thus decreasing drug absorption. Carbamazepine reduces the plasma concentrations of Doperidol

Coma, bone marrow suppression or phaeochromocytoma.

Caution is advised in patients with liver disease, renal failure, patients with Parkinson disease, arteriosclerosis, cardiac symptoms and functional brain impairment. Patients with hyperthyroidism and patients receiving lithium. Doperidol should be used with extreme care in children.

Use in Pregnancy and lactation:
Doperidol should not be used.

Carton pack contains 2 blisters each of 10 tablets of 5, 10 or 20mg, or bottle of 15ml drops, with leaflet.


© 2010 Domina Pharmaceuticals